InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,477.90
(
0.16%
)
US TECH 100
19,196.00
(
-0.10%
)
Dow Jones
39,127.80
(
0.00%
)
Brent Oil
85.00
(
0.62%
)
Bitcoin
61,358.65
(
0.90%
)
Post# of 252391
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119931
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 193693

Wednesday, 03/01/2017 12:06:21 PM

Wednesday, March 01, 2017 12:06:21 PM

Post# of 252391
ABBV/ENTA—FDA expands Technivie* label to include GT4 patients with CP-A cirrhosis:

https://content.govdelivery.com/accounts/USFDA/bulletins/18a3b91

From a commercial standpoint, this label expansion won’t move the needle for ABBV/ENTA since GT4 is a small population in the US (about 6% of all HCV patients) and the GT4 CP-A population is even smaller. Please see #msg-115667263 for related info.

*Technivie is the US brand name for the 2-DAA variant of Viekira Pak that omits Dasabuvir (the non-nuke third agent).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up